Why the study?
Does the choice of direct oral anticoagulant (dabigatran, rivaroxaban, or apixaban) affect the risk of stroke, systemic embolism, or major bleeding in patients with non-valvular atrial fibrillation?
Population
Patients with non-valvular atrial fibrillation
Comparison
Direct oral anticoagulants vs Indirect comparison against each other
Design
Meta-analysis
Key result
The provided text contains only the journal's editorial board information and no clinical study data.
Authors
Loading...
No data available; leaves comparative DOAC bleeding risks in non-valvular AF unresolved pending head-to-head trials.
Meta-Analysis
Does the choice of direct oral anticoagulant (dabigatran, rivaroxaban, or apixaban) affect the risk of stroke, systemic embolism, or major bleeding in patients with non-valvular atrial fibrillation?
Indirect comparisons suggest apixaban may have a more favorable major bleeding profile than dabigatran 150 mg or rivaroxaban, though these findings require confirmation in direct head-to-head randomized trials.
Ansell et al. (2012) conducted a meta-analysis in atrial fibrillation. dabigatran, rivaroxaban, apixaban was evaluated. The provided text contains only the journal's editorial board information and no clinical study data.